GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » EV-to-EBITDA

OKYO Pharma (OKYO Pharma) EV-to-EBITDA : -3.62 (As of May. 22, 2024)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OKYO Pharma's enterprise value is $47.69 Mil. OKYO Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-13.18 Mil. Therefore, OKYO Pharma's EV-to-EBITDA for today is -3.62.

The historical rank and industry rank for OKYO Pharma's EV-to-EBITDA or its related term are showing as below:

OKYO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.46   Med: 0   Max: 0
Current: -3.62

OKYO's EV-to-EBITDA is ranked worse than
100% of 456 companies
in the Biotechnology industry
Industry Median: 10.52 vs OKYO: -3.62

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), OKYO Pharma's stock price is $1.47. OKYO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.164. Therefore, OKYO Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


OKYO Pharma EV-to-EBITDA Historical Data

The historical data trend for OKYO Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma EV-to-EBITDA Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -6.37

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -6.37

Competitive Comparison of OKYO Pharma's EV-to-EBITDA

For the Biotechnology subindustry, OKYO Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OKYO Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's EV-to-EBITDA falls into.



OKYO Pharma EV-to-EBITDA Calculation

OKYO Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=47.691/-13.184
=-3.62

OKYO Pharma's current Enterprise Value is $47.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OKYO Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-13.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OKYO Pharma  (NAS:OKYO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

OKYO Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.47/-0.164
=At Loss

OKYO Pharma's share price for today is $1.47.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OKYO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.164.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


OKYO Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


OKYO Pharma (OKYO Pharma) Business Description

Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA